617 total citations 20 papers, 509 citations indexed
About
Pratt Cb is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Pratt Cb has authored 20 papers receiving a total of 509 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Pratt Cb's work include Cancer therapeutics and mechanisms (4 papers), Sarcoma Diagnosis and Treatment (4 papers) and Cancer Treatment and Pharmacology (3 papers). Pratt Cb is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Sarcoma Diagnosis and Treatment (4 papers) and Cancer Treatment and Pharmacology (3 papers). Pratt Cb collaborates with scholars based in United States. Pratt Cb's co-authors include Evans We, Donald Pinkel, Neil Senzer, Gaston K. Rivera, Sidnei Epelman, N Jaffe, W R Crom, Sally L. George, Ellen Shanks and H. Omar Hustu and has published in prestigious journals such as Blood, PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).
In The Last Decade
Pratt Cb
20 papers
receiving
464 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Pratt Cb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pratt Cb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pratt Cb more than expected).
This network shows the impact of papers produced by Pratt Cb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pratt Cb. The network helps show where Pratt Cb may publish in the future.
Co-authorship network of co-authors of Pratt Cb
This figure shows the co-authorship network connecting the top 25 collaborators of Pratt Cb.
A scholar is included among the top collaborators of Pratt Cb based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Pratt Cb. Pratt Cb is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Cb, Pratt. (1996). Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.. PubMed. 23(3 Suppl 6). 84–90.5 indexed citations
2.
Arnold, Bernd, et al.. (1992). Recombinant human TNF-alpha stimulates the secretion of granulocyte colony-stimulating factor in vivo.. PubMed. 6(4). 319–22.9 indexed citations
3.
Cb, Pratt, Sidnei Epelman, & N Jaffe. (1987). Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients.. PubMed. 71(4). 421–3.19 indexed citations
Cb, Pratt, et al.. (1986). Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults.. PubMed. 70(6). 703–9.28 indexed citations
6.
Cb, Pratt, et al.. (1984). Cisplatin and doxorubicin for locally recurrent and metastatic childhood rhabdomyosarcoma.. PubMed. 3(4). 207–10.4 indexed citations
7.
Cb, Pratt, et al.. (1983). Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin.. PubMed. 67(1). 85–8.7 indexed citations
8.
Cb, Pratt, et al.. (1982). Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study.. PubMed. 65(11-12). 1021–6.31 indexed citations
9.
Cb, Pratt. (1981). Selected applications of methotrexate alone and in combination in osteosarcoma.. PubMed. 65 Suppl 1. 107–11.2 indexed citations
10.
Senzer, Neil, et al.. (1979). Tetany: a complication of cis-dichlorodiammineplatinum(II) therapy.. PubMed. 63(4). 547–8.21 indexed citations
Cb, Pratt, et al.. (1978). Evaluation of a chemotherapeutic regimen for primary liver cancer in children.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 62(9). 1403–4.5 indexed citations
13.
Rivera, Gaston K., et al.. (1978). Phase I study of neocarzinostatin in children with cancer.. PubMed. 62(12). 2105–7.3 indexed citations
14.
Cb, Pratt, et al.. (1978). Age-related adriamycin cardiotoxicity in children.. PubMed. 62(9). 1381–5.64 indexed citations
15.
Cb, Pratt, et al.. (1978). Combination chemotherapy for osteosarcoma.. PubMed. 62(2). 251–7.22 indexed citations
16.
We, Evans, et al.. (1977). Recovery from toxicity associated with high-dose methotrexate: prognostic factors.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(5). 797–804.42 indexed citations
17.
Cb, Pratt, et al.. (1975). Coordinated treatment of childhood rhabdomyosarcoma.. PubMed. 6. 87–94.8 indexed citations
18.
Cb, Pratt, et al.. (1972). Coordinated treatment of childhood rhabdomyosarcoma with surgery, radiotherapy, and combination chemotherapy.. PubMed. 32(3). 606–10.124 indexed citations
19.
Cb, Pratt, et al.. (1968). Combination therapy including vincristine (NSC-67574) for malignant solid tumors in children.. PubMed. 52(4). 489–95.15 indexed citations
20.
Cb, Pratt, et al.. (1962). Chemotherapy of metastatic retinoblastoma.. PubMed. 16. 435–7.17 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.